Literature DB >> 25092148

Polycystic kidney disease: Kidney volume--a crystal ball for ADPKD prognosis?

Emilie Cornec-Le Gall1, Yannick Le Meur1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25092148     DOI： 10.1038/nrneph.2014.132

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  8 in total

1.  Type of PKD1 mutation influences renal outcome in ADPKD.

Authors:  Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Jian-Min Chen; Maryvonne Hourmant; Marie-Pascale Morin; Régine Perrichot; Christophe Charasse; Bassem Whebe; Eric Renaudineau; Philippe Jousset; Marie-Paule Guillodo; Anne Grall-Jezequel; Philippe Saliou; Claude Férec; Yannick Le Meur
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

2.  Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; James E Bost; Vicente E Torres; Lisa Guay-Woodford; Kyongtae Ty Bae; Douglas Landsittel; Jie Li; Bernard F King; Diego Martin; Louis H Wetzel; Mark E Lockhart; Peter C Harris; Marva Moxey-Mims; Mike Flessner; William M Bennett; Jared J Grantham
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-16       Impact factor: 8.237

3.  Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Authors:  María V Irazabal; Laureano J Rangel; Eric J Bergstralh; Sara L Osborn; Amber J Harmon; Jamie L Sundsbak; Kyongtae T Bae; Arlene B Chapman; Jared J Grantham; Michal Mrug; Marie C Hogan; Ziad M El-Zoghby; Peter C Harris; Bradley J Erickson; Bernard F King; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 10.121

4.  Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.

Authors:  Andreas L Serra; Diane Poster; Andreas D Kistler; Fabienne Krauer; Shagun Raina; James Young; Katharina M Rentsch; Katharina S Spanaus; Oliver Senn; Paulus Kristanto; Hans Scheffel; Dominik Weishaupt; Rudolf P Wüthrich
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

5.  Everolimus in patients with autosomal dominant polycystic kidney disease.

Authors:  Gerd Walz; Klemens Budde; Marwan Mannaa; Jens Nürnberger; Christoph Wanner; Claudia Sommerer; Ulrich Kunzendorf; Bernhard Banas; Walter H Hörl; Nicholas Obermüller; Wolfgang Arns; Hermann Pavenstädt; Jens Gaedeke; Martin Büchert; Christoph May; Harald Gschaidmeier; Stefan Kramer; Kai-Uwe Eckardt
Journal:  N Engl J Med       Date:  2010-06-26       Impact factor: 91.245

6.  Volume progression in polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres; Arlene B Chapman; Lisa M Guay-Woodford; Kyongtae T Bae; Bernard F King; Louis H Wetzel; Deborah A Baumgarten; Phillip J Kenney; Peter C Harris; Saulo Klahr; William M Bennett; Gladys N Hirschman; Catherine M Meyers; Xiaoling Zhang; Fang Zhu; John P Miller
Journal:  N Engl J Med       Date:  2006-05-18       Impact factor: 91.245

7.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.

Authors:  Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

8.  Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.

Authors:  Anna Caroli; Norberto Perico; Annalisa Perna; Luca Antiga; Paolo Brambilla; Antonio Pisani; Bianca Visciano; Massimo Imbriaco; Piergiorgio Messa; Roberta Cerutti; Mauro Dugo; Luca Cancian; Erasmo Buongiorno; Antonio De Pascalis; Flavio Gaspari; Fabiola Carrara; Nadia Rubis; Silvia Prandini; Andrea Remuzzi; Giuseppe Remuzzi; Piero Ruggenenti
Journal:  Lancet       Date:  2013-08-21       Impact factor: 79.321
  8 in total
  3 in total

1.  Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Authors:  Olivier Devuyst; Arlene B Chapman; Ron T Gansevoort; Eiji Higashihara; Ronald D Perrone; Vicente E Torres; Jaime D Blais; Wen Zhou; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2016-12-05       Impact factor: 10.121

2.  Polycystic kidney disease. HALTing PKD progression--revival of blood pressure control.

Authors:  Thomas Benzing
Journal:  Nat Rev Nephrol       Date:  2014-12-16       Impact factor: 28.314

3.  Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients.

Authors:  Laura Girardat-Rotar; Julia Braun; Milo A Puhan; Alison G Abraham; Andreas L Serra
Journal:  BMC Nephrol       Date:  2017-07-17       Impact factor: 2.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.